Monocyte chemoattractant protein-1 promoter-2518 polymorphism and schizophrenia in the Korean population

Psychiatric Genetics

Volumn 14, Issue 2, 2004, Pages 65-67

  Pae, Chi Un ^a   Chung, Kyoo In ^b   Kim, Jung Jin ^a   Yu, Hye Sook ^a   Lee, Chang Uk ^a   Lee, Soo Jung ^a   Lee, Chul ^a   Jun, Tae Youn ^a   Serretti, Alessandro ^c   Paik, In Ho ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Monocyte chemoattractant protein 1 promoter 2518 polymorphism; Schizophrenia

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

BASE SEQUENCE; CHEMOKINE CCL2; DNA; DNA PRIMERS; HUMANS; KOREA; PROMOTER REGIONS (GENETICS); REFERENCE VALUES; SCHIZOPHRENIA; SEQUENCE DELETION;

EID: 2942637989     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ypg.0000128764.07344.06     Document Type: Article

References (26)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington, DC: American Psychiatric Association.
2. Arolt V, Weitzsch C, Wilke I, Nolte A, Pinnow M, Rothermundt M, et al. (1997). Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res 66:145-152.
3. Arolt V, Rothermundt M, Wandinger KP, Kirchner H (2000). Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5:150-158.
4. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M (2001). Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 6:79-82.
5. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, et al. (1998). Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 22:947-957.
6. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV-Clinician Version (SCID-CV). Washington DC: American Psychiatric Press.
7. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, et al. (1995). Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 52:668-672.
8. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ (2000). Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404:407-411.
9. Hwang SY, Cho ML, Park B, Kim JY, Kim YH, Min DJ, et al. (2002). Allelic frequency of the MCP-1 promoter -2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult-onset Still's disease. Eur J Immunogenet 29:413-416.
10. Kaminska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszen M (2001). Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp 49:439-445.
11. Kaneko H, Ogasawara H, Naito T, Akimoto H, Lee S, Hishikawa T, et al. (1999). Circulating levels of beta-chemokines in systemic lupus erythematosus. J Rheumatol 26:568-573.
12. Karpus WJ, Lukacs NW, Kennedy KJ, Smith WS, Hurst SD, Barrett TA (1997). Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol 158:4129-4136.
13. Kay SR, Opler LA, Lindenmayer JP (1988). Reliability and validity of the positive and negative syndrome scafe for schizophrenics. Psychiatry Res 23:99-110.
14. Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura GJ, Pioli R, Boin F, et al. (2002). Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophren Res 54:281-291.
15. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995). Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29:141-152.
16. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM (1997). Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159:2994-2999.
17. Müller N, Riedel M, Ackenheil M, Schwarz MJ (1999). The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249 (suppl 4):IV62-IV68.
18. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM (1997). A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophren Res 26:227-233.
19. Omata N, Yasutomi M, Yamada A, Iwasaki H, Mayumi M, Ohshima Y (2002). Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response. J Immunol 169:4861-4866.
20. Riedel M, Kronig H, Schwarz MJ, Engel RR, Kuhn KU, Sikorski C, et al. (2002). No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 252:232-234.
21. Rothermundt M, Arolt V, Bayer TA (2001). Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 15:319-339.
22. Rovin BH, Lu L, Saxena R (1999). A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259:344-348.
23. Schwarz MJ, Muller N, Riedel M, Ackenheil M (2001). The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 56:483-486.
24. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK (1999). Elevated interleukin-6 in schizophrenia. Psychiatry Res 87:129-136.
25. Villemain F, Chatenoud L, Galinowski A, Homo-Delarche F, Ginestet D, Loo H, et al. (1989). Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 146:609-616.
26. + cells in medication-free patients with schizophrenia. J Psychiatr Res 36:331-336.